구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | N803 (Nogapendekin Alfa Inbakicept, Nogapendekin Alfa Inbakicept (N803)) Vadim S Koshkin·Metastatic Urothelial Carcinoma 53 trials |
|---|---|
Overview Program | Nogapendekin Alfa Inbakicept (N803) |
Overview Company | Vadim S Koshkin |
Overview Modality | ADC |
Overview Target | Metastatic Urothelial Carcinoma |
Overview Indication | Metastatic Urothelial Carcinoma; Urothelial Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Payload | vedotin (BT8009) and dual-ADC combinations with |
MoA Mechanism | targeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor |
MoA Biomarker | biomarker-driven patient selection to optimize clinical outcomes |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Unknown |
Clinical Selected reported efficacy | ORR 80% |
Clinical Reported ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02384954 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | N803 (Nogapendekin Alfa Inbakicept, Nogapendekin Alfa Inbakicept (N803)) Vadim S Koshkin·Metastatic Urothelial Carcinoma 53 trials |
|---|---|
Overview Program | Nogapendekin Alfa Inbakicept (N803) |
Overview Company | Vadim S Koshkin |
Overview Modality | ADC |
Overview Target | Metastatic Urothelial Carcinoma |
Overview Indication | Metastatic Urothelial Carcinoma; Urothelial Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Payload | vedotin (BT8009) and dual-ADC combinations with |
MoA Mechanism | targeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor |
MoA Biomarker | biomarker-driven patient selection to optimize clinical outcomes |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Unknown |
Clinical Selected reported efficacy | ORR 80% |
Clinical Reported ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02384954 |
추천 비교
추천 비교